Medtronic Inc. MDT

Medtronic is undergoing a significant transformation by spinning off its diabetes division, MiniMed Group, with plans to achieve an $8 billion valuation. This move aims to sharpen the company's focus on core operations, particularly following the FDA's recent approval of its Hugo robotic surgery system. Despite facing stock challenges, Medtronic reported strong year-over-year revenue growth of 8.7%, showcasing its financial resilience. The company continues to handle market volatility while redirecting approximately $350 million towards innovation in its primary business segments, reinforcing its commitment to growth in the healthcare sector.